期刊文献+

辛伐他汀对铜和高胆固醇阿尔茨海默病家兔海马淀粉样肽前蛋白mRNA表达的影响 被引量:2

Effect of simvastatin on hippocampus APP mRNA expression in copper-cholesterol AD rabbit model
下载PDF
导出
摘要 目的研究辛伐他汀对铜和高胆固醇诱导的阿尔茨海默病(AD)家兔海马淀粉样肽前蛋白(APP)mRNA表达的影响。方法采用Sparks方法复制铜和高胆固醇诱导的AD家兔模型。辛伐他汀(5mg·kg-1·d-1)灌胃3w,高效液相色谱法(HPLC)检测家兔海马胆固醇含量,实时定量RT-PCR法检测海马APP mRNA表达水平。分析海马胆固醇含量与海马APP mRNA表达的相关性。结果模型组海马胆固醇含量及APP mRNA表达水平显著高于正常组(P<0.05)。辛伐他汀组海马胆固醇含量及APP mRNA表达水平显著低于模型组(P<0.05);与正常组相无显著差别(P>0.05)。海马APP mRNA表达水平与海马胆固醇含量呈正相关(r=0.58,P<0.05)。结论辛伐他汀可通过降低海马胆固醇含量减少APP转录,这可能是辛伐他汀降低AD发病的机制。 Objective To study the effect of simvastatin on hippocampus APP mRNA expression in copper-cholesterol AD rabbits.Methods The copper-cholesterol rabbit AD model was replicated referring to Sparks method.Simvastatin was used to treat the rabbits by gastric perfusion at a dose of 5 mg·kg-1·d-1 for 3 weeks. High performance liquid chromatography(HPLC) was used to detect cholesterol levels in rabbit hippocampus,RT-PCR to detect the expression of APP mRNA levels in hippocampus.The correlation between cholesterol content and APP mRNA expression of the rabbit hippocampus was analyzed.Results The cholesterol content and the expression of APP mRNA levels were significantly increased in model group,the difference was significant compared with normal group(P0.05).Hippocampus cholesterol content and APP mRNA expression was significantly decreased in simvastatin group,there was significant difference compared with model group(P0.05);no significant difference compared with normal group(P0.05).The level of the hippocampus cholesterol and hippocampus APP mRNA expression was positively correlated(r=0.58,P0.05).Conclusions Simvastatin can reduce APP transcription of the hippocampus by reducing cholesterol levels,which may be the mechanism of simvastatin reducing AD incidence.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2011年第3期443-444,共2页 Chinese Journal of Gerontology
基金 天津市自然科学基金资助项目(08JCYBJC10800) 高校博士点专项基金(20101210120008)
关键词 胆固醇 海马 AD APP mRNA Copper Cholesterol Hippocampus AD APP mRNA
  • 相关文献

参考文献7

  • 1Kivipelto M,Helkala EL,Laakso MP,et al.Midlife vascular risk factors and Alzheimer's disease in later life:longitudinal,population based study[J].BMJ,2001;322(7300):1447-51.
  • 2Mori T,Paris D,Town T,et al.Cholesterol accumulates in senile plaques of Alzheimer's disease patients and in transgenic APP(SW)mice[J].J Neuropathol Exp Neurol,2001;60(8):778-85.
  • 3Lovell MA,Robertson JD,Teesdale WJ,et al.Copper iron and zinc in Alzheimer's disease senile plaques[J].J Neurol Sci,1998;158(1):47-52.
  • 4Sparks DL,Schreurs BG.Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease[J].Proc Natl Acad Sci U S A,2003;100(19):11065-9.
  • 5Wolozin B,Kellman W,Ruosseau P,et al.Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme a reductase inhibitors[J].Arch Neurol,2000;57(10):1439-43.
  • 6Frears ER,Stephens DJ,Walters CE,et al.The role of cholesterol in the biosynthesis of beta-amyloid[J].Neuroreport,1999;10(8):1699-705.
  • 7郝峻巍,李琳.胆固醇代谢异常与阿尔采末病[J].生理科学进展,2005,36(1):64-67. 被引量:3

二级参考文献10

  • 1Marx J. Alzheimer's disease: BAD for the heart, BAD for the mind? Science, 2001,294 : 508 -509.
  • 2Helmuth L. New therapies: New Alzheimer's treatments thatmay ease the mind. Science, 2002,297 : 1260 - 1262.
  • 3Lesser G, Kandiah K, Libow LS, et al. Elevated serum totaland LDL cholesterol in very old patients with Alzheimerg dis-ease. Dement Geriatr Cogn Disord, 2001,12 : 138145.
  • 4Okabe S, Kim HD, Miwa A, et al. Continual remodeling of postsynaptic density and its regulation by synaptic activity.Nat Neurosci, 1999,2 : 804 - 811.
  • 5Papassotiropoulos A, Lutjohann D, Bagli M, et al. Heun R24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res,2002, 36 : 27 -32.
  • 6Petanceska SS, DeRosa S, Sharma A, et al. Changes inapolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci,2003,20 : 395 -406.
  • 7Ehehalt R, Keller P, Haass C, et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol, 2003,160 : 113 - 123.
  • 8Kakio A, Nishimoto SI, Yanagisawa K, et al. Cholesteroldependent formation of GM1 ganglioside-bound amyloid betaprotein, an endogenous seed for Alzheimer amyloid. J Biol Chem, 2001, 276 : 24985 -24990.
  • 9Distl R, Meske V, Ohm TG. Tangle-bearing neurons contain more free cholesterol than ADjacent tangle-free neurons.Acta Neuropathol (Berl). 2001,101 : 547-554.
  • 10Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease:the cholesterol connection. Nat Neurosci, 2003,6 : 345-351.

共引文献2

同被引文献13

  • 1邵蓓丽,李焰生.他汀类药物用于痴呆的预防和治疗[J].神经病学与神经康复学杂志,2009,6(2):137-141. 被引量:3
  • 2顾萍,蒋卫民.他汀类药物防治阿尔茨海默病的作用机制[J].中国老年学杂志,2005,25(2):221-222. 被引量:11
  • 3郝峻巍,李琳.胆固醇代谢异常与阿尔采末病[J].生理科学进展,2005,36(1):64-67. 被引量:3
  • 4杨瑞丽,钟伟,崔嫣.辛伐他汀对轻、中度老年痴呆合并高脂血症病人疗效的影响[J].中华神经医学杂志,2006,5(12):1261-1263. 被引量:8
  • 5Wolozin B. Cholesterol, statins and dementia[J]. Curr Op-in LipidoU 2004,15(6):667.
  • 6Sparks DL, Sabbagh MN, Conno DJ, et al, Atorvastatinfor the treatment of mild to moderate Alzheimer disease [J].Arch Neurol,2005,62(5):753.
  • 7Li J,Zhang M, Xu ZQ,et al. Vascular risk aggravatesthe progression of Alzheimer ’ s disease in a Chinese cohort[J]. JAlzheimers Dis,2010,20(2) :491.
  • 8Locatelli S, Lutiohann D,Schmidt HH,et al. Reductionof plasma 24S-hydroxycholesterol (cerebrosterol) levelsusing high-dosage simvastatin in patients with hypercho-lesterolemia: evidence that simvastatin affects cholesterol-metabolism in the human brain[J], Arch Neurol,2002,59(2):213.
  • 9Stepien K, Tomaszew S, Czuczwar SJ. Neuroprotectiveproperties of statins [J]. Pharmacol Rep, 2005,57(5) :561.
  • 10Naidu A, Xu P, Catalano R, et al. Secretion of apolipo-protein E by statins [J], Brain, 2002,958( 1):100.

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部